AlphAIalphai — Financial news for AI agents
yahoo.comAUG 223 min read$SPRY

ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript

ARS Pharma (SPRY) reported Q2 2026 U.S. net product revenue of $26.2M, with total market share reaching 5%, up from 2.5% YoY. Neffy's market share in targeted areas hit 8%, driven by 16,000+ unique prescribers. The company aims to expand into the CSU market and expects cash flow breakeven by late 2027. Total revenue was $33.7M, with operating expenses at $95.1M. ARS plans to reduce SG&A and R&D expenses by over 40% in the second half of 2026.

Original reporting
yahoo.com
Published Aug 22, 2026, 3:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 3:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript — source image
Source · yahoo.com
Decision brief

The 30-second read

$SPRYNeutralMed
01

Why it matters

The disclosed financials and guidance provide fresh data for valuation models and may influence short‑term price action.

02

Market read

Earnings data and guidance are directly relevant to traders with positions in SPRY and the broader biotech sector.

03

What to watch

Potential regulatory hurdles for the intranasal epinephrine platform and competitive pressure from traditional injectors.

Relevance 8/10Novelty 8/10Timing: Q2 2026 earnings release

Background

ARS Pharma (SPRY) presented its Q2 2026 earnings, highlighting revenue growth, market‑share expansion for its neffy product, and revised expense guidance.

Company-level read

Ticker impact

$SPRYNeutralHigh confidence
Context

Q2 2026 earnings call disclosed net product revenue of $26.2M, total revenue $33.7M, cash $143.8M and revised SG&A/R&D expense guidance for H2 2026.

Expected impact

Potential modest upside if cost reductions are achieved; downside risk if SG&A remains high.

Evidence & confidence

First‑report earnings numbers and forward expense guidance provide fresh material for valuation adjustments.

Market effects

Sector

Positive signal for biotech/rare‑disease therapeutics as intranasal epinephrine platform shows commercial traction.

Regional

U.S. biotech sector may see modest uplift from ARS Pharma's market‑share gains in the CSU space.

Global

Limited to investors tracking emerging biotech earnings and pipeline progress.

Counterpoint

What could challenge this read

High SG&A spend could erode margins; cash burn may delay breakeven if revenue growth slows.

Key entities

  • Executive
    Meg Smith

    New Chief Commercial Officer announced during the call.

Read at source← All news

Related articles

AUG 21
$SPRYMed

ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share

ARS Pharmaceuticals (SPRY) reported Q2 2026 earnings, with Neffy's US market share doubling to 5% YoY. CEO Donn Casale outlined priorities including targeted commercial efforts and cost cuts. Revenue was $33.7M, with operating expenses at $95.1M. The company plans to reduce spending by over 40% in H2 2026 and aims for cash flow breakeven by late 2027. Short interest is high at 31.17% of the float.

insidermonkey.com2 min
AUG 18
$SPRYMedAI 8/10

ARS Pharma Refocuses Strategy As Q2 Revenue Hits $33.7M

ARS Pharmaceuticals (SPRY) reported Q2 2026 revenue of $33.7M, up from $15.7M a year earlier, driven by $26.2M U.S. net product revenue from neffy. Net loss widened to $62.3M ($0.63/share). The company cut broad consumer ads, targeted high-volume prescribers, appointed Meg Smith CCO, and expects H2 2026 SG&A and R&D of $114M-$126M.

rttnews.com6 min
AUG 14
$SPRYMed

ARS Pharmaceuticals Q2 Earnings Call Highlights

ARS Pharmaceuticals (NASDAQ:SPRY) said it expanded its field sales force and will target high-value prescribers, noting neffy has about 8% market share in the field-targeted universe versus ~1% in non-targeted. Commercial coverage is 90%. Q2 operating expenses were $95.1M. ARS expects cash-flow breakeven by end-2027 and Phase IIb CSU interim data in Q1 2027.

yahoo.com6 min
AUG 13
$SPRYMed

ARS Pharmaceuticals, Inc. (SPRY): Results of Operations and Financial Condition

ARS Pharmaceuticals, Inc. (SPRY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 spry-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results $26.2 million in U.S. neffy ® net product revenue in Q2 2026; total U.S. epinephrin

SEC EDGAR 8-K7 min
JUL 15
$SPRYMed

ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO

ARS Pharmaceuticals (NASDAQ:SPRY) said CEO Richard Lowenthal will stop working for the company, effective July 6. Donn Casale, then President, was appointed CEO and Director, taking over July 7. The company also reported payer access updates for neffy, noting no new coverage decisions in the July 1 cycle and continued availability via direct coverage and a retail cash option.

yahoo.com4 min
JUL 9
$SPRYMed

What's Going on With ARS Pharma Stock Thursday? - ARS Pharmaceuticals (NASDAQ:SPRY)

ARS Pharmaceuticals (NASDAQ:SPRY) announced a leadership change. Co-founder and CEO Richard Lowenthal stepped down as employee and officer effective July 6, 2026. Donn Casale, president, was appointed CEO and director effective July 7, 2026. William Blair and analyst Lachlan Hanbury-Brown discussed a more cautious neffy outlook, lowering Q2 neffy revenue to $26.4M and fair value to $21 from $31; SPRY was down 1.6% to $7.97.

benzinga.com3 min